The aim of this study is to assess subjects' satisfaction linked to the pan facial management of rejuvenation with injections of Azzalure® and Restylane® fillers. This will be an open, multi-centre study.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
60
Powder for solution for injection
Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
Galderma investigational site
Bordeaux, France
Galderma investigational site
Metz, France
Galderma investigational site
Madrid, Spain
Galderma investigational site
London, United Kingdom
Galderma investigational site
Subject Satisfaction for the Full Face
based on the subject's satisfaction questionnaire
Time frame: Month 6
Global Aesthetic Improvement From Baseline
The scale responses are: -1 indicating "worse", 0 indicating "no change", 1 indicating "improved", 2 indicating "much improved" and 3 indicating "very much improved".
Time frame: Week 3
Related Adverse Event
Number of subjects reporting related adverse events
Time frame: Month 6
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Street, United Kingdom